ATXS Astria Therapeutics Inc
- 9.490
- -0.220-2.27%
- 9.490
- 0.0000.00%
Astria Therapeutics Inc News
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Astria Therapeutics (ATXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
HC Wainwright & Co. : The Astria Therapeutics (ATXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $22 price target.
Astria TherapeuticS GAAP EPS of -$0.38 Misses by $0.02
Astria Therapeutics (ATXS.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.38 dollars, previous value of -0.40 dollars, expected value of -0.35 dollars.
Astria Therapeutics (ATXS.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.38 dollars, previous value of -0.40 dollars, expected value of -0.35 dollars.
Astria Therapeutics Q1 2024 GAAP EPS $(0.38), Inline
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate.
Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS
Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS
Astria Therapeutics 1Q Loss/Shr 38c >ATXS
Astria Therapeutics 1Q Loss/Shr 38c >ATXS
Press Release: Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update -- ALPHA-STAR Phase 1b/2 Trial Initial Proof-of-Concept Results Support Potential for STAR-0215 to Bec
Astria Therapeutics Inc | 10-Q: Quarterly report
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $16
HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics with a Buy and lowers the price target from $18 to $16.
In the Wake of Astria Therapeutics, Inc.'s (NASDAQ:ATXS) Latest US$51m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions
Key Insights Given the large stake in the stock by institutions, Astria Therapeutics' stock price might be vulnerable to their trading decisions 52% of the business is held by the top 7 shareholders
Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc(ATXS.US) Officer Sells US$135.94K in Common Stock
$Astria Therapeutics Inc(ATXS.US)$ Officer Morabito Christopher sold 10,000 shares of Common Stock on Apr 1, 2024 at an average price of $13.5939 for a total value of $135.94K.Source: Announcement Wha
Form 144 | Astria Therapeutics Inc(ATXS.US) Officer Proposes to Sell 135.94K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Astria Therapeutics Inc(ATXS.US)$ Officer CHRIS MORABITO intends to sell 10,000 shares of its common stock on Apr 1, with a total market value of approximately $135.94K
Astria Therapeutics Is Maintained at Outperform by Wedbush
Astria Therapeutics Is Maintained at Outperform by Wedbush
Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22
Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $17 to $22.
Astria Therapeutics Price Target Raised to $27.00/Share From $22.00 by Jefferies
Astria Therapeutics Price Target Raised to $27.00/Share From $22.00 by Jefferies
Analysis
Price Target
No Data
